19 citations
,
October 2019 in “Clinical and Experimental Dermatology” This study found that spironolactone significantly reduced pain, lesion count, and disease severity in patients with hidradenitis suppurativa, as reported in multiple patient cohorts.
1 citations
,
September 2020 in “Actas Dermo-Sifiliográficas” This article discusses the underutilization of spironolactone in dermatology for conditions like acne, highlighting its potential benefits and good safety profile, but reports no new clinical findings.
9 citations
,
June 2020 in “Actas Dermo-Sifiliográficas” This source suggests that spironolactone, a potassium-sparing diuretic, is underutilized in dermatology despite evidence showing its potential benefits for female acne, hidradenitis suppurativa, and female androgenetic alopecia, noting its long-term safety and reduced need for additional testing in young women.
3 citations
,
March 2024 in “International Journal of Women’s Dermatology” This study observed that spironolactone improved hidradenitis suppurativa in over 80% of female patients at 3 and 6 months, with no significant differences in response due to menstrual flares or polycystic ovarian syndrome, but mild adverse events were reported.
December 2021 in “Journal of pharmaceutical research international” This review discusses the potential and varied uses of spironolactone in dermatological conditions such as acne, hidradenitis suppurativa, hirsutism, and female pattern androgenetic alopecia, emphasizing dosage, treatment recommendations, and adverse effects for practical clinical use.